[go: up one dir, main page]

WO2025019600A3 - Modulateurs de la neurodégénérescence - Google Patents

Modulateurs de la neurodégénérescence Download PDF

Info

Publication number
WO2025019600A3
WO2025019600A3 PCT/US2024/038402 US2024038402W WO2025019600A3 WO 2025019600 A3 WO2025019600 A3 WO 2025019600A3 US 2024038402 W US2024038402 W US 2024038402W WO 2025019600 A3 WO2025019600 A3 WO 2025019600A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
present disclosure
benzo
radiolabeled
neurodegenerative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/038402
Other languages
English (en)
Other versions
WO2025019600A2 (fr
Inventor
Changning Wang
Stephen Neil GOMPERTS
Ping Bai
Tim Bartels
Vikram Khurana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Brigham and Womens Hospital Inc
General Hospital Corp
Original Assignee
UCL Business Ltd
Brigham and Womens Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd, Brigham and Womens Hospital Inc, General Hospital Corp filed Critical UCL Business Ltd
Publication of WO2025019600A2 publication Critical patent/WO2025019600A2/fr
Publication of WO2025019600A3 publication Critical patent/WO2025019600A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne, par exemple, des composés benzo[c][1,2,5]thiadiazolyles et des méthodes d'utilisation de ces composés, par exemple, pour le traitement de troubles neurodégénératifs tels que la maladie de Parkinson (MP), l'atrophie multisystématisée (AMS) et la démence à corps de Lewy. <i /> <i /> La présente invention concerne également des composés benzo[c][1,2,5]thiadiazolyle radiomarqués avec un radio-isotope, tel que 11C, 18F, ou 123/125I, et un procédé d'utilisation des composés radiomarqués pour des agents d'imagerie cérébrale par tomographie par émission de positons (TEP) ou par tomographie par émission monophotonique (TEMP) afin de diagnostiquer des troubles neurodégénératifs et/ou surveiller leur traitement.
PCT/US2024/038402 2023-07-18 2024-07-17 Modulateurs de la neurodégénérescence Pending WO2025019600A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363527516P 2023-07-18 2023-07-18
US63/527,516 2023-07-18

Publications (2)

Publication Number Publication Date
WO2025019600A2 WO2025019600A2 (fr) 2025-01-23
WO2025019600A3 true WO2025019600A3 (fr) 2025-02-27

Family

ID=94282566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/038402 Pending WO2025019600A2 (fr) 2023-07-18 2024-07-17 Modulateurs de la neurodégénérescence

Country Status (1)

Country Link
WO (1) WO2025019600A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014366A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives hetero biaryle inhibiteurs de la metalloprotease matricielle
US20080064729A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
US20170298056A1 (en) * 2014-05-08 2017-10-19 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of hiv-1 entry and methods of use thereof
WO2018172250A1 (fr) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014366A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives hetero biaryle inhibiteurs de la metalloprotease matricielle
US20080064729A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
US20170298056A1 (en) * 2014-05-08 2017-10-19 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of hiv-1 entry and methods of use thereof
WO2018172250A1 (fr) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND 18 January 2016 (2016-01-18), XP093284073, Database accession no. 110785434 *
DATABASE PUBCHEM COMPOUND 29 January 2018 (2018-01-29), XP093284076, Database accession no. 132022949 *

Also Published As

Publication number Publication date
WO2025019600A2 (fr) 2025-01-23

Similar Documents

Publication Publication Date Title
Bushara et al. Modality-specific frontal and parietal areas for auditory and visual spatial localization in humans
Scheffel et al. In vivo detection of short‐and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain
Chien et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808
Perani et al. Left and right hemisphere contribution to recovery from neglect after right hemisphere damage—an [18F] FDG PET study of two cases
Sarubbo et al. Complete recovery after surgical resection of left Wernicke's area in awake patient: a brain stimulation and functional MRI study
Canini et al. Semantic interference and its control: A functional neuroimaging and connectivity study
Peterson et al. How changes in brain activity and connectivity are associated with motor performance in people with MS
Ko et al. Brain stimulation and functional imaging with fMRI and PET
Kolodziej et al. SPECT-imaging of activity-dependent changes in regional cerebral blood flow induced by electrical and optogenetic self-stimulation in mice
Freudenmann et al. Delusional infestation: neural correlates and antipsychotic therapy investigated by multimodal neuroimaging
Rao et al. Fractional amplitude of low-frequency fluctuation changes in monkeys with spinal cord injury: a resting-state fMRI study
Liu et al. Electrical brain activity during human walking with parametric variations in terrain unevenness and walking speed
WO2025019600A3 (fr) Modulateurs de la neurodégénérescence
Apetz et al. Effects of subthalamic deep brain stimulation on striatal metabolic connectivity in a rat hemiparkinsonian model
WO2025019589A3 (fr) Modulateurs de la neurodégénérescence
EP1002548A3 (fr) Procédé de détermination des effets des stimuli externes sur le cerveau à l&#39;aide de la Tomographie par émission de positrons
Ventre‐Dominey et al. Dissociable dorsal and ventral frontostriatal working memory circuits: evidence from subthalamic stimulation in Parkinson's disease
DE69822300D1 (de) 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
Kim et al. Assessment of cerebral glucose metabolism in cat deafness model: strategies for improving the voxel-based statistical analysis for animal PET studies
Busan et al. Transcranial magnetic stimulation and preparation of visually-guided reaching movements
Molchan et al. A double FDG/PET study of the effects of scopolamine in older adults
Chivate et al. PET/CT in autism, a diagnostic tool
Middleton Fundamental and clinical evidence for basal ganglia influences on cognition
Hurd et al. Chapter IX Human forebrain dopamine systems: characterization of the normal brain and in relation to psychiatric disorders
Zhu et al. PET mapping for brain-computer-interface-based stimulation in a rat model with intracranial electrode implantation in the ventro-posterior medial thalamus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24843917

Country of ref document: EP

Kind code of ref document: A2